Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Should We Use Renin-Angiotensin-Aldosterone System Inhibitors Routinely in Patients With Hypertrophic Cardiomyopathy?

  • Jae-Hyeong Park (Department of Cardiology in Internal Medicine, Chungnam National University, School of Medicine, Chungnam National University Hospital)
  • Received : 2023.06.13
  • Accepted : 2023.06.25
  • Published : 2023.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Maron BJ, Desai MY, Nishimura RA, et al. Management of hypertrophic cardiomyopathy: JACC state-ofthe-art review. J Am Coll Cardiol 2022;79:390-414.
  2. Lee HJ, Kim J, Chang SA, Kim YJ, Kim HK, Lee SC. Major clinical issues in hypertrophic cardiomyopathy. Korean Circ J 2022;52:563-75.
  3. Park CS, Rhee TM, Lee HJ, et al. Prognostic and safety implications of renin-angiotensin-aldosterone system inhibitors in hypertrophic cardiomyopathy: a real-world observation over 2,000 patients. Korean Circ J 2023;53:606-18.
  4. Youn JC, Kim D, Cho JY, et al. Korean Society of Heart Failure guidelines for the management of heart failure: treatment. Korean Circ J 2023;53:217-38.
  5. Zhang Y, Liu MH, Zhang M, et al. Different clinical characteristics and outcomes of hypertrophic cardiomyopathy with and without hypertension: seeking the truth. J Geriatr Cardiol 2023;20:109-20.
  6. Ho CY, Day SM, Axelsson A, et al. Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med 2021;27:1818-24.
  7. Kim KH, Pereira NL. Genetics of cardiomyopathy: clinical and mechanistic implications for heart failure. Korean Circ J 2021;51:797-836.